Ocrevus Use Still Growing in Europe But Challenges on Horizon, Spherix Reports
From: Multiple Sclerosis News Today By: Marta Figueiredo Prescriptions of Roche’s Ocrevus (ocrelizumab) among multiple sclerosis (MS) patients initiating or switching a disease-modifying…
Newest Oral DMTs Haven’t Yet Made a Big Impact in the MS World
From: MDedge Neurology By: Bruce Jancin The three oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) approved last year in the United States haven’t made a big splash in…
Gastroenterologists Continue Down Rocky Road to Recovery
From: Becker’s GI & Endoscopy By: Eric Oliver Gastroenterologists continue to feel the resonating effects of the COVID-19 pandemic as they work to return operations to pre-pandemic levels, according to a report from Spherix Global Insights